Payment overview · 2025
General Payments
$1,331.86
63 reported records · 14 companies
Healthcare provider profile · identity verified
Jesse Andrew Stoff, MD
Allopathic & Osteopathic Physicians|Allergy & Immunology · GLEN COVE, NY · NPI 1477637312
Verified facts
What the public records show
CMS Open Payments records show Jesse Andrew Stoff, MD received $1,331.86 in general payments during 2025 across 63 reported records.
ABBVIE INC. accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Creon by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Zenpep by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $502.09 | 37.7% | 29 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $232.76 | 17.5% | 9 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $97.74 | 7.3% | 5 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $92.44 | 6.9% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $81.06 | 6.1% | 3 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $67.99 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.21 | 3.8% | 2 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $46.91 | 3.5% | 2 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $39.78 | 3.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.07 | 2.0% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $24.82 | 1.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $23.53 | 1.8% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $23.53 | 1.8% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $21.93 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,331.86 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $502.09 | 29 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $232.76 | 9 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $97.74 | 5 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $81.06 | 3 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $68.87 | 3 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $67.99 | 2 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $46.91 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $39.78 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 71 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
71 | 23 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Armour Thyroid | Thyroid,pork | 108 | 16 |
| Metformin Hcl Er | Metformin Hcl | 74 | 16 |
| Creon | Lipase/Protease/Amylase | 71 | 23 |
| Alprazolam | Alprazolam | 46 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 43 | 16 |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 40 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 30 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Gabapentin | Gabapentin | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Xtandi | Enzalutamide | 19 | suppressed |
| Zoledronic Acid | Zoledronic Acid | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Lynparza | Olaparib | 13 | suppressed |
| Piqray | Alpelisib | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Taltz Autoinjector | Ixekizumab | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Brukinsa | Zanubrutinib | 11 | suppressed |
| Buphenyl | Sodium Phenylbutyrate | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,331.86 · 63 records | ABBVIE INC. | CREON, Cologuard Collection Kit, ERLEADA, Hizentra, JEMPERLI, LINZESS, NP Thyroid 60, Orserdu, PANCREAZE, QSYMIA, RUBRACA, Sucraid, The Cologuard Plus Collection Kit, VIBERZI, XT CDX, Xembify, ZEJULA, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error